8 research outputs found
Children and adolescents with pulmonary arterial hypertension : baseline and follow-up data from the polish registry of pulmonary hypertension (BNP-PL)
We present the results from the pediatric arm of the Polish Registry of Pulmonary
Hypertension. We prospectively enrolled all pulmonary arterial hypertension (PAH) patients,
between the ages of 3 months and 18 years, who had been under the care of each PAH center
in Poland between 1 March 2018 and 30 September 2018. The mean prevalence of PAH was
11.6 per million, and the estimated incidence rate was 2.4 per million/year, but it was geographically
heterogeneous. Among 80 enrolled children (females, n = 40; 50%), 54 (67.5%) had PAH associated
with congenital heart disease (CHD-PAH), 25 (31.25%) had idiopathic PAH (IPAH), and 1 (1.25%)
had portopulmonary PAH. At the time of enrolment, 31% of the patients had significant impairment
of physical capacity (WHO-FC III). The most frequent comorbidities included shortage of growth
(n = 20; 25%), mental retardation (n = 32; 40%), hypothyroidism (n = 19; 23.8%) and Down syndrome
(n = 24; 30%). The majority of children were treated with PAH-specific medications, but only half of
them with double combination therapy, which improved after changing the reimbursement policy.
The underrepresentation of PAH classes other than IPAH and CHD-PAH, and the geographically
heterogeneous distribution of PAH prevalence, indicate the need for building awareness of PAH
among pediatricians, while a frequent coexistence of PAH with other comorbidities calls for a
multidisciplinary approach to the management of PAH children
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
Physical Performance, Toxicity, and Quality of Life as Assessed by the Physician and the Patient
The Impact of COVID-19 pandemic on children with pulmonary arterial hypertension. parental anxiety and attitudes. Follow-up Data from the Polish Registry of Pulmonary Hypertension (BNP-PL)
The COVID-19 pandemic has impacted healthcare systems worldwide. Little is known about the impact of the pandemic on medical and psycho-social aspects of children with rare diseases such as pulmonary arterial hypertension and their parents. The study is based on children registered in The Database of Pulmonary Hypertension in the Polish Population and a parent-reported survey deployed during the first 6 months of the pandemic. The questionnaire consisted of six question panels: demographic data, fear of COVID-19, General Anxiety Disorder-7 (GAD-7), social impact of pandemic, patients’ medical status, and alarming symptoms (appearance or exacerbation). Out of 80 children registered, we collected 58 responses (72.5% response rate). Responders (parents) were mostly female (n = 55; 94.8%) at a mean age of 40.6 ± 6.9 years. Patients (children) were both females (n = 32; 55%) and males with a mean age of 10.0 ± 5.1 years. Eleven (19%) children had symptoms of potential disease exacerbation. Eight parents (72.7%) decided for watchful waiting while others contacted their GPs or cardiologists (n = 6; 54.5%). Three children had to be hospitalized (27.3%). Most planned hospitalizations (27/48; 56.2%) and out-patient visits (20/35; 57.1%) were cancelled, delayed, or substituted by telehealth services. Among the participating parents, the study shows very high levels of anxiety (n = 20; 34.5%) and concern (n = 55; 94.8%) and the need for detailed information (52; 89.6%) regarding COVID-19 and medical service preparedness during the pandemic. The COVID-19 pandemic has influenced child healthcare and caused high levels of anxiety among parents
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Treatment with adjuvant trastuzumab for 1 year improves disease-free survival and overall survival in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We aimed to assess disease-free survival and overall survival after a median follow-up of 4 years for patients enrolled on the Herceptin Adjuvant (HERA) trial.Clinical Trial, Phase IIIJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tSCOPUS: ar.jinfo:eu-repo/semantics/publishe